Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02490930 | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | completed | Early Phase 1 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 13, 2017 | clinicaltrials |
| NCT00187486 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | completed | Phase 2 | 66 | University of California, San FranciscoOTHER | 1 | Sep 5, 2017 |
| clinicaltrials |
| NCT01240161 | Personalized Translational Platform for Biomarker Discovery in Brain Tumors | completed | — | 37 | Marcelo F. Di Carli, MD, FACCOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT02439164 | Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma | completed | N/A | 36 | Beijing Tiantan HospitalOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT00003470 | Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma(AA) | completed | Phase 2 | 27 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00003477 | Antineoplaston Therapy in Treating Children With Visual Pathway Glioma(VPG) | completed | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01191346 | Radiation Planning Study for High Grade Brain Tumors | completed | — | 24 | University of CincinnatiOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02029573 | Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma(ART) | completed | Phase 2 | 36 | King Fahad Medical CityOTHER_GOV | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00727506 | BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | completed | Phase 2 | 151 | Boehringer IngelheimINDUSTRY | 2 | Aug 15, 2017 | clinicaltrials |
| NCT00540722 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01975116 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | completed | Phase 1 | 18 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 7, 2017 | clinicaltrials |
| NCT02887417 | Glioblastoma Platelet Activation Study(GPAS) | completed | — | 21 | University Medicine GreifswaldOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 59 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | completed | Phase 2 | 45 | University of WashingtonOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00694330 | Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor | completed | Phase 1 | 11 | Massachusetts General HospitalOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00686725 | Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) | completed | Phase 4 | 99 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 14, 2017 | clinicaltrials |
| NCT01149109 | Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients(CeTeG) | completed | Phase 3 | 141 | University Hospital, BonnOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | completed | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00424554 | Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) | completed | Phase 2 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00684567 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | completed | Phase 2 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00345163 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)(BRAIN) | completed | Phase 2 | 167 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00660543 | MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy | completed | N/A | 14 | OHSU Knight Cancer InstituteOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT00335075 | Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) | completed | Phase 3 | 151 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00783393 | SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) | completed | Phase 2 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00589706 | A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas | completed | Phase 2 | 11 | Drexel University College of MedicineOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01393912 | PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma | completed | Phase 1 | 55 | St. Jude Children's Research HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01792505 | Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma | completed | Phase 1 | 71 | Cedars-Sinai Medical CenterOTHER | 1 | Apr 21, 2017 | clinicaltrials |
| NCT02550249 | Neoadjuvant Nivolumab in Glioblastoma(Neo-nivo) | completed | Phase 2 | 29 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00916409 | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | completed | Phase 3 | 700 | NovoCure Ltd.INDUSTRY | 12 | Apr 10, 2017 | clinicaltrials |
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01268566 | A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 62 | MedImmune LLCINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01929720 | Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors(FOCUS) | completed | N/A | 33 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT02278510 | Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma | completed | Early Phase 1 | 3 | Michael Vogelbaum, MD, PhDOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00883298 | Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 30 | Center for Neurosciences, TucsonOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT02607397 | ROCOCO - Low Grade Glioma - Planning Study(ROCOCO LGG) | completed | — | 25 | Maastricht Radiation OncologyOTHER | 2 | Mar 28, 2017 | clinicaltrials |
| NCT00792012 | A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma | completed | Phase 1 | 37 | University of Colorado, DenverOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT03082846 | Treatment of High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial | completed | N/A | 16 | Xue XiaoyingOTHER | 0 | Mar 21, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT01280552 | A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) | completed | Phase 2 | 124 | Precision Life Sciences GroupINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00459381 | Pazopanib in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00185848 | Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis | completed | Phase 1 | 10 | Sanjiv Sam GambhirOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT00859222 | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | completed | Phase 1 / Phase 2 | 51 | Patrick Y. Wen, MDOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT01738646 | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | completed | Phase 2 | 48 | Duke UniversityOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01836536 | Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients(AVA-CELL) | completed | N/A | 30 | Center Eugene MarquisOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT01250470 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02300532 | Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study) | completed | — | 561 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 27, 2017 | clinicaltrials |
| NCT01220271 | A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 / Phase 2 | 75 | Eli Lilly and CompanyINDUSTRY | 3 | Feb 16, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 13, 2017source: clinicaltrials